A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy
Sushanth Gouni(The University of Texas MD Anderson Cancer Center), Paolo Strati(The University of Texas MD Anderson Cancer Center), Brian Hess(Washington University in St. Louis), Allison Rosenthal(Mayo Clinic Hospital), Lei Feng(Ministry of Public Security of the People's Republic of China), Madiha Iqbal(Mayo Clinic in Florida), Amy Ayers(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Reid W. Merryman(Harvard University), Grace Watson, Arushi Khurana(Mayo Clinic in Arizona), Jennifer L. Crombie(Dana-Farber Cancer Institute), Manali Kamdar(University of Colorado Cancer Center), Yi Lin, Andrew Ip(Hackensack University Medical Center)
Cited by 1
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial
|The American Journal of Medicine|2015|740
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience
|British Journal of Haematology|2014|364